申请人:Ono Pharmaceutical Co. Ltd.
公开号:US04178367A1
公开(公告)日:1979-12-11
Prostaglandin I.sub.2 analogues of the formula: ##STR1## (wherein Y represents trans-vinylene or ethylene, R.sup.1 represents hydrogen or an alkyl group containing from 1 to 12 carbon atoms, R.sup.2 represents hydrogen, methyl or ethyl, R.sup.3 represents a single bond, or an alkylene group containing from 1 to 4 carbon atoms, R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, each represent hydrogen or an alkyl group containing from 1 to 8 carbon atoms, n represents 3, 4, 5 or 6, the wavy line attached to the carbon atoms in positions 11 and 15 depicted in the formula represents .alpha.- or .beta.-configuration or mixtures thereof, and the double bond between C.sub.6 -C.sub.6 is Z or E) are new compounds possessing pharmacological properties typical of prostaglandins, for example PGI.sub.2.
公式为:##STR1##(其中Y代表反式乙烯或乙烯,R.sup.1代表氢或含有1到12个碳原子的烷基,R.sup.2代表氢、甲基或乙基,R.sup.3代表单键或含有1到4个碳原子的烷基,R.sup.4、R.sup.5和R.sup.6,可能相同也可能不同,每个代表氢或含有1到8个碳原子的烷基,n代表3、4、5或6,公式中所示的连接到位置11和15的碳原子的波浪线代表α-或β-构型或其混合物,C.sub.6 -C.sub.6之间的双键是Z或E)的前列腺素I.sub.2类似物是具有前列腺素典型药理特性的新化合物,例如PGI.sub.2。